 |
|
|
| |
Switching to Integrase Strand Transfer Inhibitors
and the Risk of Diabetes in Persons with HIV
|
| |
| |
CROI 2024 March 3-6 Denver
Y. Joseph Hwang1, Catherine R. Lesko2; Todd T. Brown1,2; G. Caleb Alexander1,2; Jeanne C Keruly1; LaQuita N. Snow1; Jarratt D. Pytell3;
Oluwaseun Falade-Nwulia1; Richard D. Moore1,2; Anthony Todd Fojo1 for the Johns Hopkins HIV Clinical Cohort
1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
3. Department of Medicine, University of Colorado School of Medicine, Aurora, CO
in my opinion, there’s no risk simply by switch, only if there’s weight gain, and the its due to weight gain, not InSTI. Switch to DTG from PI may improve glucose. Jules Levin
BICTEGRAVIR and DOLUTEGRAVIR have no impact on glucose levels 12 months after initiation
Dolutegravir and Insulin Resistance
Bictegravir alters glucose tolerance and metabolism
|
| |
|
|
|
|
|
